Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 94

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 94
---
, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the underwriting
discounts and commissions and estimated offering expenses payable by us.

Each $0.25 increase or
decrease in the assumed initial public offering price of $11.00 per Ordinary Share, which is the midpoint of the price range set
forth on the cover page of this prospectus, would increase (decrease), the net proceeds to us from this offering by $0.23 million, assuming
the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of
Ordinary Shares we are offering. An increase (decrease) of 100,000 in the number of Ordinary Shares offered by us would increase
(decrease) the net proceeds to us from this offering by $1.01 million, assuming no change in the assumed initial public offering
price and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

We currently expect to use
the net proceeds from this offering for the following purposes:

| ● | approximately $4.5 million                                                                                                    
 for development activities (including the completion of our pivotal trial) and preparation of the PMA submission for GelrinC; |

| ● | approximately $1.0 million                                      
 for operations (manufacturing, regulatory affairs and patents); |

| ● | approximately $0.5 million               
 for research and development activities; |

| ● | approximately $0.5 million                                                          
 for EU marketing development (Medical Device Regulation qualification and scaleup); |

| ● | approximately $1.1 million for                                                                                                            
 the repayment of the Bridge Loan, the loans under the 2024 Loan Agreements, the 2025 Loan Agreements and the December 2024 Loan Agreement 
 and accrued interest and applicable risk premium;                                                                                         |

| ● | $0.25 million to be paid to the Chairman of our                                                                                  
 board of directors in consideration of his services to the Company since 2019, for which he has not received compensation, which 
 was approved by our shareholders on March 20, 2025;                                                                              |

| ● | $0.43 million                                             
 for payment of the CSL Settlement (as defined below); and |

| ● | the remainder for working capital and general corporate 
 purposes and possible future